We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+36.17%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$622M
AUM Growth
+$149M
Cap. Flow
+$50.8M
Cap. Flow %
8.17%
Top 10 Hldgs %
69.69%
Holding
34
New
10
Increased
3
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
VRDN icon
Viridian Therapeutics
VRDN
+$19M
2
THRD
Third Harmonic Bio
THRD
+$18.4M
3
SNDX icon
Syndax Pharmaceuticals
SNDX
+$16.6M
4
AKRO
Akero Therapeutics
AKRO
+$11.4M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$10.9M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$23.2M
2
KURA icon
Kura Oncology
KURA
+$14.3M
3
VTGN icon
VistaGen Therapeutics
VTGN
+$11.5M
4
COGT icon
Cogent Biosciences
COGT
+$8.56M
5
TNYA icon
Tenaya Therapeutics
TNYA
+$2.01M

Sector Composition

Rank Sector Weight
1 Healthcare 99.6%
2 Financials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
1
Cogent Biosciences
COGT
$6.79B
$64.5M 10.36%
4,319,940
-624,768
-13% -$8.56M
XENE icon
2
Xenon Pharmaceuticals
XENE
$6.32B
$57.6M 9.26%
1,594,932
– –
VRDN icon
3
Viridian Therapeutics
VRDN
$2.13B
$55.3M 8.89%
2,696,340
+1,057,731
+65% +$19M
BLU
4
DELISTED
BELLUS Health Inc.
BLU
$54.2M 8.71%
5,128,557
+648,773
+14% +$6.89M
MRUS
5
DELISTED
Merus
MRUS
$52.4M 8.43%
2,615,762
– –
CYTK icon
6
Cytokinetics
CYTK
$11B
$43.3M 6.96%
893,646
– –
ACRS icon
7
Aclaris Therapeutics
ACRS
$730M
$37.9M 6.1%
2,410,622
– –
AKRO
8
DELISTED
Akero Therapeutics
AKRO
$25.3M 4.07%
+743,472
New +$11.4M
STSA
9
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$22.3M 3.58%
3,711,286
– –
TCDA
10
DELISTED
Tricida, Inc. Common Stock
TCDA
$20.7M 3.33%
1,975,403
-53,050
-3% -$580K
CBAY
11
DELISTED
Cymabay Therapeutics
CBAY
$20.1M 3.23%
5,738,500
– –
THRD
12
DELISTED
Third Harmonic Bio
THRD
$19.3M 3.11%
+1,018,569
New +$18.4M
SNDX icon
13
Syndax Pharmaceuticals
SNDX
$1.84B
$17.7M 2.85%
+738,110
New +$16.6M
CLDX icon
14
Celldex Therapeutics
CLDX
$2.77B
$15.1M 2.44%
538,812
– –
DAWN
15
DELISTED
Day One Biopharmaceuticals
DAWN
$14.8M 2.38%
739,661
– –
ARWR icon
16
Arrowhead Research
ARWR
$12.1B
$13.4M 2.15%
404,078
+91,545
+29% +$3.69M
KURA icon
17
Kura Oncology
KURA
$922M
$12.3M 1.98%
899,407
-927,084
-51% -$14.3M
ABOS icon
18
Acumen Pharmaceuticals
ABOS
$154M
$11M 1.77%
+1,100,000
New +$6.31M
KPTI icon
19
Karyopharm Therapeutics
KPTI
$168M
$10.6M 1.7%
129,041
– –
ALLK
20
DELISTED
Allakos
ALLK
$10.1M 1.62%
+1,643,500
New +$6.88M
ALPN
21
DELISTED
Alpine Immune Sciences Inc
ALPN
$9.54M 1.53%
+1,325,000
New +$10.9M
CELC icon
22
Celcuity
CELC
$4.03B
$9.24M 1.49%
920,464
– –
ENTA icon
23
Enanta Pharmaceuticals
ENTA
$372M
$5.37M 0.86%
+103,494
New +$6.05M
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$4.54M 0.73%
312,553
– –
RZLT icon
25
Rezolute
RZLT
$480M
$3.31M 0.53%
1,210,000
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q3 2022 Portfolio in Review

As of Q3 2022, Commodore Capital held 34 positions worth $622M, up 31% from $473M the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Commodore Capital deployed $50.8M of net new capital in Q3 2022, opening 10 new positions and adding to 3 existing holdings. Its largest new stake was Third Harmonic Bio: 1,018,569 shares worth $19.3M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Kura Oncology, an estimated $14.3M trimmed.

  • Commodore Capital's largest Q3 2022 buy was Third Harmonic Bio: 1,018,569 shares worth $19.3M.
  • Commodore Capital added most to Viridian Therapeutics in Q3 2022, an estimated $19M increase.
  • Commodore Capital's biggest Q3 2022 reduction was Kura Oncology, cutting an estimated $14.3M.
  • Commodore Capital fully exited IVERIC bio, Inc. Common Stock in Q3 2022, selling an estimated $23.2M.
  • Commodore Capital's ten largest holdings make up 70% of its $622M portfolio in Q3 2022.
  • Commodore Capital opened 10 new positions and closed 4 in Q3 2022.
  • Commodore Capital's portfolio value rose 31% quarter-over-quarter to $622M.

Based on Commodore Capital's 13F filing for Q3 2022, filed 14 Nov 2022.